



CreditRiskMonitor's assessment of Rite Aid Corporation's ("Rite Aid")
"high risk" status has been determined by a combination of factors:

Monthly Average FRISK® Score	Page 2
The FRISK® Score Components	3
Company Report Detail	4
FRISK® Deep Dive and Adjusted Market Cap Volatility	5
FRISK® Stress Index	6
Peer Analysis on Alternate Suppliers and Customers	7
Quarterly Performance Ratios	8
Quarterly Leverage Ratios	9
Quarterly Liquidity Ratios and Rates of Return	10
Year-Over-Year Statement of Cash Flows	11
.....	
About This Report/Contact CreditRiskMonitor	12

MONTHLY AVERAGE FRISK® SCORE

CreditRiskMonitor's proprietary FRISK® score signals that Rite Aid Corporation (NYS: RAD) **has a 10 to 50 times greater risk of bankruptcy** than the average public company.

Business Name	2018				2019								
	S	O	N	D	J	F	M	A	M	J	J	A	S
Rite Aid Corporation	2	2	2	1	1	1	1	1	1	1	1	1	1

The FRISK® score is 96% accurate* in predicting the risk of corporate failure/bankruptcy over a 12-month horizon. All FRISK® scores are recalculated every night for each subsequent 12-month period.

Probability of bankruptcy within 12 months			
FRISK®		From	To
Best	10	0.00%	0.12%
	9	0.12%	0.27%
	8	0.27%	0.34%
	7	0.34%	0.55%
	6	0.55%	0.87%
	5	0.87%	1.40%
	4	1.40%	2.10%
	3	2.10%	4.00%
	2	4.00%	9.99%
	1	9.99%	50.00%
	Worst		

While the percentage risk of bankruptcy varies at each FRISK® score, 96% of public companies that eventually go bankrupt enter the FRISK® "red zone" prior to filing. **A FRISK® score of 5 or less is an important warning sign.**

* FRISK® score accuracy of 96% is based on backtesting of U.S. public companies; results may vary by country.

THE FRISK® SCORE COMPONENTS

At the core of the CreditRiskMonitor process is our 96% accurate FRISK® score, which indicates a company's level of financial stress on a scale of 1 to 10, based on the probability of bankruptcy over a 12-month horizon. When available, the FRISK® score incorporates a number of powerful risk indicators including:

A “Merton” type model using stock market capitalization and volatility

Financial ratios, including those used in the Altman Z”-Score Model

Bond agency ratings from Moody’s, Fitch, & DBRS

Crowdsourced CreditRiskMonitor Usage Data

Crowdsourcing has enhanced the accuracy and timeliness of the FRISK® score. We collect and analyze data patterns from thousands of CreditRiskMonitor subscribers, including professionals from more than 35% of the Fortune 1000 and other large corporations worldwide.

The crowdsourcing advantage is even more powerful in our FRISK® score since many of the professionals who use our service are credit managers:

- Credit managers control one of the largest sources of working capital going into a company
- They are not held to the same “Fair Disclosure” restrictions that prevent non-disclosed information sharing on public companies
- Credit managers use a variety of non-public information sources such as their own company’s management and sales representatives to be alerted to concerns in a public company’s performance
- It is commonly known credit managers confidentially share information with other credit managers, thus collectively, their behavior helps to provide advanced insight to financial problems in public companies

[Read more in Credit Research Foundation’s quarterly journal article, “Assessing Public Company Financial Risk by Crowdsourcing the Research of Credit Professionals”](#)

COMPANY REPORT DETAIL

Rite Aid Corporation

Phone: (717) 761-2633

30 Hunter Ln
CAMP HILL, PA 17011-2400 United States

Ticker: **RAD**

Latest Financial Statements as of 6/1/2019

Business Summary

Rite Aid Corporation is a retail drugstore chain. The Company's segments include Retail Pharmacy and Pharmacy Services. As of March 2, 2019, the Company operated 2,469 stores in 18 states across the country. The Company's Retail Pharmacy segment consists of Rite Aid stores, RediClinic and Health Dialog. It sells brand and generic prescription drugs, as well as an assortment of front-end products, including health and beauty aids, personal care products, seasonal merchandise, and a private brand product line. Its front-end products include over-the-counter medications, health and beauty aids, personal care items, cosmetics, household items, food and beverages, greeting cards, seasonal merchandise and numerous other everyday and convenience products. The Company's Pharmacy Services segment consists of EnvisionRx, which provides a range of pharmacy benefit services.

(Source: 10-K)

Employees: 53,100 (as of 3/2/2019)

Incorporated: 4/15/1968

Federal Tax Id: 231614034

Credit Score History

[Why are these scores different?](#)

FRISK® Score Analysis

Score/ Index	2018				2019											
	S	O	N	D	J	F	M	A	M	J	J	A	S			
FRISK® Score*	2	2	2	1	1	1	1	1	1	1	1	1	1	1	1	1
DBT Index	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	DBT
Z"-Score	-0.68			-0.73				-0.72					-0.85			Z"


*FRISK® Scores are month-end

- Probability of bankruptcy within 12 months is 10% to 50%.
- Trade payments are prompt, "cloaking" the risk.
- Bonds are rated as non-investment grade ("junk") by 2 different rating agencies.
- Market Capitalization has declined by 71% over the last 12 months.
- Total Liabilities are 24 times larger than Market Capitalization.
- Financial statement ratios indicate financial stress.


The FRISK® score is a 96% accurate method by which to monitor public company bankruptcy risk.

Payment performance, captured by the Days Beyond Terms (DBT) index, which is very similar to D&B's PAYDEX® score, is not an effective indicator of financial stress for publicly traded companies since they often continue to pay on time right up until their bankruptcy filing. This is what's commonly called the "Cloaking Effect."

Days Sales Outstanding



FRISK® DEEP DIVE



The FRISK® score relative to the broader Retail (Drugs) industry raises an additional red flag signaling heightened risk relative to peers, as well...

MAKING IMMEDIATE ATTENTION REQUIRED.

ADJUSTED MARKET CAP VOLATILITY



One of the inputs of the FRISK® score is a company's market cap volatility, adjusted for dividends, over the course of a year. Incorporating this information allows us to capture the "wisdom of markets" on a daily basis. This ensures our subscribers are getting the most up to date view of the risks they face since stocks tend to be more liquid and faster moving than bond prices and ratings.

FRISK® STRESS INDEX

#	Business Name	Country	FRISK® score
1	CENTRIC HEALTH Corp	Canada	1
2	Diplomat Pharmacy Inc	United States	1
3	Rite Aid Corporation	United States	1
4	Aptechnaya set' 36,6" PAQ	Russian Federation	3
5	Diego Pellicer Worldwide Inc	United States	3
6	Progressive Care, Inc.	United States	3
7	STWC Holdings Inc	United States	3
8	China Jo-Jo Drugstores Inc	China	4
9	Farmacias Benavides SAB de CV	Mexico	4
10	Genky DrugStores Co Ltd	Japan	4

FRISK® Stress Index - SIC classification: Drug stores and proprietary stores

☒ Primary industry codes only ☐ Primary and secondary industry codes

Businesses From: All Businesses

CLEAR


In Industry: SIC 5912: Drug stores and proprietary stores

Country: All Countries

UPDATE RESULTS

Scale: Auto

Total Companies in all months: 128



The FRISK® Stress Index shows the collective probability of failure in a group of companies (such as an industry, country or portfolio) over the next 12 months. It is designed to show trends in risk level across groups of companies and is shown on a zero to 50 scale, with 50 being the most risky.

The average probability of failure for SIC code 5912 (Drug stores and proprietary stores) has increased 49% since 2007. Rite Aid is among the weakest names in the industry as evidenced by its FRISK® score of 1.

PEER ANALYSIS ON ALTERNATE SUPPLIERS AND CUSTOMERS

The Peer Analysis expands to provide a ranking of a company's competitors, which can help provide options for alternate suppliers or new customers

SIC classification: Drug stores and proprietary stores^x

Calendar Year/Quarter: 2019.2

Businesses in Peer Group: 736	Ranking Within Peer Group	Number Of Peers Ranked	Company Value	Peer Group Range		
				Low	Median	High
Credit Ratings						
Z-Score	142	154	-0.85	-1,057.05	2.47	376.05
Performance ratios:						
Net Sales (Thousands of U.S. Dollars)	5	21	5,372,589	55	270,876	63,431,000
Gross Margin % Of Sales	108	158	20.97	-489.50	27.22	100.00
Gross Margin % Of Sales -- TTM	108	158	21.43	-183.66	27.55	110.55
SGA % Of Sales	88	159	21.64	1.45	20.38	1,412.76
SGA % Of Sales -- TTM	87	159	21.28	1.47	20.04	2,289.88
Operating Margin % Of Sales	142	163				
Operating Margin % Of Sales -- TTM	142	163				
EBITDA Margin Of Sales	62	74				
EBITDA Margin Of Sales -- TTM	70	85				
Net Profit Margin % Of Sales	144	163				
Net Profit Margin % Of Sales -- TTM	145	163				
Pre-tax Income % Of Sales	143	163				
Effective Tax Rate	8	160				
Depreciation % Of Prop/Plant/Equipment	32	133				
Capital Expense % Of Prop/Plant/Equipment	24	109				
Interest Coverage	54	66	0.80	-339.19	4.82	23,801.00
Interest Coverage -- TTM	66	80	-0.27	-79.09	5.47	17,264.00
Liquidity ratios:						
Cash Ratio	138	156	0.07	0.00	0.25	41.85
Quick Ratio	76	148	0.70	0.03	0.71	42.78
Current Ratio	62	156	1.45	0.00	1.27	44.66
Efficiency ratios:						
Accounts Receivable Turnover	69	155	11.96	0.04	9.43	2,289.76
Days Sales Outstanding	77	163	39.51	0.00	34.14	8,764.67
% of Inventory Financed by Vendors	90	135				
% of Inventory Financed by Vendors -- TTM	96	141				
Inventory Turnover	48	153				
Inventory Turnover -- TTM	44	155				
Days Sales in Inventory	48	150				
Inventory to Working Capital	75	147				
Accounts Payable Turnover	22	150				
Accounts Payable Turnover -- TTM	22	151				
Leverage & debt coverage:						
Total Debt to Equity Ratio	141	143				
Debt to Tangible Equity Ratio		127		0.00	0.75	215.04
Total Debt to Assets Ratio	112	142	0.34	0.00	0.25	0.91
Short-Term Debt % of Total Debt	2	142	0.32	0.15	35.41	100.00
Short-Term Debt % of Working Capital	11	144	0.92	-5,483.33	8.99	13,795.25
Liabilities to Net Worth Ratio		124		0.00	1.68	271.78
Total Liabilities to Equity Ratio	148	152	9.17	0.00	1.31	54.90
TTM EBITDA to Total Debt	66	72	-0.02	-10.95	0.25	2,555.07
Net Debt to TTM EBITDA		66		-51.05	2.25	18.69

Rank	Company Name
1	Homology Medicines Inc
2	YSS Corp
3	Petmed Express Inc
4	Green Thumb Industries Inc
5	HLS Therapeutics Inc

Rank	Company Name
1	NewLeaf Brands Inc
2	Petmed Express Inc
3	Homology Medicines Inc
4	Green Thumb Industries Inc
5	YSS Corp

Green - Ranked in Upper Quartile of Peer Group
 White - Ranked in the Middle Two Quartiles of Peer Group
 Red - Ranked in Lower Quartile of Peer Group
 Orange - Confidential
 Grey - Data is Not Available

TTM = trailing 12 months
 N/A = Not Available

Rite Aid Corporation demonstrates bottom quartile ranking in key financial ratios (shown in red) versus its industry peers.

QUARTERLY PERFORMANCE RATIOS

Recurring
operating
and
net losses

Negative
free cash
flow

Performance Ratios - Sequential Quarters

(Thousands of U.S. Dollars)

Period Ended	13 weeks 6/1/2019	13 weeks 3/2/2019	13 weeks 12/1/2018	13 weeks 9/1/2018	13 weeks 6/2/2018
Net Sales \$	\$5,372,589	\$5,379,645	\$5,450,060	\$5,421,362	\$5,388,490
% change	-0.13%	-1.29%	0.53%	0.61%	-0.11%
Gross Margin \$	\$1,126,723	\$1,164,364	\$1,182,088	\$1,161,151	\$1,168,749
% change	-3.23%	-1.50%	1.80%	-0.65%	-7.96%
% of sales	20.97%	21.64%	21.69%	21.42%	21.69%
change as % of incremental sales	n/m	n/m	72.96%	-23.11%	n/m
SG&A \$	\$1,162,652	\$1,143,202	\$1,142,555	\$1,153,991	\$1,152,627
% change	1.70%	0.06%	-0.99%	0.12%	-2.48%
% of sales	21.64%	21.25%	20.96%	21.29%	21.39%
change as % of incremental sales	n/m	n/m	-39.85%	4.15%	n/m
Operating margin \$	(\$36,407)	(\$34,736)	\$36,905	(\$407,639)	\$5,709
% change	-4.81%	-194.12%	109.05%	-7,240.29%	102.58%
% of sales	-0.68%	-0.65%	0.68%	-7.52%	0.11%
change as % of incremental sales	n/m	n/m	1,549.04%	-1,257.45%	n/m
EBITDA \$	\$50,231	\$78,995	\$123,972	(\$312,931)	\$106,097
% change	-36.41%	-36.28%	139.62%	-394.95%	186.44%
% of sales	0.93%	1.47%	2.27%	-5.77%	1.97%
change as % of incremental sales	n/m	n/m	1,522.42%	-1,274.73%	n/m
EBIT \$	(\$33,695)	(\$7,930)	\$37,287	(\$402,674)	\$11,568
% change	-324.91%	-121.27%	109.26%	-3,580.93%	105.35%
% of sales	-0.63%	-0.15%	0.68%	-7.43%	0.21%
change as % of incremental sales	n/m	n/m	1,533.07%	-1,260.17%	n/m
Pre-tax income \$	(\$91,965)	(\$60,625)	(\$18,721)	(\$458,907)	(\$51,224)
% change	-51.69%	-223.83%	95.92%	-795.88%	80.81%
% of sales	-1.71%	-1.13%	-0.34%	-8.46%	-0.95%
change as % of incremental sales	n/m	n/m	1,533.86%	-1,240.21%	n/m
Net income (loss) \$	(\$99,659)	(\$272,979)	(\$4,510)	(\$359,140)	\$214,416
% change	63.49%	-5,952.75%	98.74%	-267.50%	-72.05%
% of sales	-1.86%	-5.07%	-0.08%	-6.62%	3.98%
change as % of incremental sales	n/m	n/m	1,235.73%	-1,744.82%	n/m
Tax expense \$	\$7,374	\$195,004	(\$1,471)	(\$106,559)	(\$9,497)
Effective tax rate	-8.02%	-321.66%	7.86%	23.22%	18.54%
Depreciation expense \$	\$56,266	\$57,953	\$57,917	\$57,243	\$59,129
% of sales	1.05%	1.08%	1.06%	1.06%	1.10%
% of capital expenses	114.38%	78.42%	100.36%	111.24%	95.95%
% of PP&E, net (annualized)	8.07%	17.53%	17.25%	16.64%	16.70%
Capital expenditures \$	\$49,191	\$73,898	\$57,707	\$51,458	\$61,626
% change	-33.43%	28.06%	12.14%	-16.50%	14.66%
% of PP&E, net (annualized)	7.05%	22.36%	17.18%	14.96%	17.40%
% of working capital (annualized)	13.38%	18.09%	14.03%	13.46%	18.60%
Interest coverage ratio	0.86	1.50	2.21	(5.56)	1.69
% change	-42.50%	-32.27%	139.78%	-429.34%	169.66%
Free cash flow \$	(\$114,307)	(\$305,514)	\$308,149	(\$323,999)	(\$151,990)
% change	62.59%	-199.14%	195.11%	-113.17%	-1.63%
Source:	10-Q	10-K	10-Q	10-Q	10-Q
	7/11/2019	4/25/2019	1/8/2019	10/4/2018	7/6/2018

QUARTERLY LEVERAGE RATIOS

Negative tangible net worth suggests that the company has exhausted all of its loanable collateral

Leverage Ratios - Sequential Quarters

(Thousands of U.S. Dollars)

Period Ended	6/1/2019	3/2/2019	12/1/2018	9/1/2018	6/2/2018
Total debt \$	\$3,616,467	\$3,494,760	\$3,436,732	\$3,526,946	\$3,182,603
% change	3.48%	1.69%	-2.56%	10.82%	-6.16%
Stockholders' equity \$	\$1,035,217	\$1,186,690	\$1,453,414	\$1,455,950	\$1,812,311
% change	-12.76%	-18.35%	-0.17%	-19.66%	13.20%
Total debt to equity ratio	3.49	2.95	2.36	2.42	1.76
% change	18.62%	24.55%	-2.39%	37.94%	-17.10%
Tangible net worth \$	(\$473,003)	(\$370,152)	(\$117,083)	(\$132,705)	(\$177,729)
% change	-27.79%	-216.15%	11.77%	25.33%	56.71%
Total assets \$	\$10,529,689	\$7,591,367	\$8,082,958	\$8,165,668	\$8,329,453
% change	38.71%	-6.08%	-1.01%	-1.97%	-7.34%
Total debt to assets ratio	0.34	0.46	0.43	0.43	0.38
% change	-25.39%	8.28%	-1.55%	13.03%	1.27%
Tangible assets \$	\$9,021,469	\$6,034,525	\$6,512,461	\$6,577,013	\$6,339,413
% change	49.50%	-7.34%	-0.98%	3.75%	-9.15%
Short-term debt \$	\$11,751	\$16,111	\$16,066	\$18,668	\$19,025
% change	-27.06%	0.28%	-13.94%	-1.88%	-8.36%
Short-term debt % of total debt	0.32%	0.46%	0.47%	0.53%	0.60%
% change	-29.52%	-1.39%	-11.68%	-11.46%	-2.34%
Short-term debt % of working capital	0.92%	0.97%	1.00%	1.11%	1.38%
% change	-5.75%	-2.65%	-10.20%	-19.46%	-15.52%
Total liabilities \$	\$9,494,472	\$6,404,677	\$6,629,544	\$6,709,718	\$6,517,142
% change	48.24%	-3.39%	-1.19%	2.95%	-11.79%
Total liabilities to equity ratio	9.17	5.40	4.56	4.61	3.60
% change	69.93%	18.32%	-1.02%	28.16%	-22.08%
Total debt to EBITDA ratio (annualized)	18.00	11.06	6.93	n/a	7.50
% change		59.59%	n/a	n/a	n/a
Source:			10-Q 1/8/2019	10-Q 10/4/2018	10-Q 7/6/2018

Total liabilities to equity & annualized total debt to EBITDA ratios worsen

QUARTERLY LIQUIDITY RATIOS AND RATES OF RETURN

The Company's cash ratio is ranked in the lower quartile of its Peer Group

Liquidity Ratios - Sequential Quarters

(Thousands of U.S. Dollars)

Period Ended	6/1/2019	3/2/2019	12/1/2018	9/1/2018	6/2/2018
Current assets \$	\$4,128,743	\$4,101,719	\$4,330,478	\$4,371,662	\$4,196,143
% change	0.66%	-5.28%	-0.94%	4.18%	-11.39%
% of short-term debt	35,135.25%	25,459.12%	26,954.30%	23,417.95%	22,055.94%
Current liabilities \$	\$2,845,143	\$2,443,135	\$2,720,325	\$2,691,597	\$2,817,094
% change	16.45%	-10.19%	1.07%	-4.45%	-18.68%
Working capital \$	\$1,283,600	\$1,658,584	\$1,610,153	\$1,680,065	\$1,379,049
% change	-22.61%	3.01%	-4.16%	21.83%	8.48%
% of sales (annualized)	5.97%	7.71%	7.39%	7.75%	6.40%
Cash \$	\$190,453	\$144,353	\$410,043	\$132,468	\$147,092
% change	31.94%	-64.80%	209.54%	-9.94%	-67.12%
% of short-term debt	1,620.74%	895.99%	2,552.24%	709.60%	773.15%
Cash ratio	0.07	0.06	0.15	0.05	0.05
% change	13.20%	-60.78%	206.30%	-5.75%	-59.57%
Quick assets \$	\$1,994,231	\$1,933,065	\$2,127,873	\$2,172,073	\$2,056,047
% change	3.16%	-9.16%	-2.03%	5.64%	-11.24%
% of short-term debt	16,970.73%	11,998.42%	13,244.57%	11,635.27%	10,807.08%
Quick ratio	0.70	0.79	0.78	0.81	0.73
% change	-11.41%	1.15%	-3.07%	10.58%	9.14%
Current ratio	1.45	1.68	1.59	1.62	1.49
% change	-13.56%	5.47%	-1.99%	9.04%	8.96%
Source:	10-Q 7/11/2019	10-K 4/25/2019	10-Q 1/8/2019	10-Q 10/4/2018	10-Q 7/6/2018

Negative rates of return in 4 of the last 5 fiscal periods

Rate of Return - Sequential Quarters

(Thousands of U.S. Dollars)

Period Ended	13 weeks 6/1/2019	13 weeks 3/2/2019	13 weeks 12/1/2018	13 weeks 9/1/2018	13 weeks 6/2/2018
Return on equity	-8.40%	-18.78%	-0.31%	-19.82%	13.39%
% change	55.29%	-5,962.59%	98.44%	-247.97%	-85.59%
Return on total assets	-1.10%	-3.48%	-0.06%	-4.35%	2.48%
% change	68.42%	-6,175.86%	98.73%	-275.86%	-67.19%
Return on tangible assets	-1.32%	-4.35%	-0.07%	-5.56%	3.22%
% change	69.58%	-6,215.38%	98.76%	-272.70%	-66.38%
Source:	10-Q 7/11/2019	10-K 4/25/2019	10-Q 1/8/2019	10-Q 10/4/2018	10-Q 7/6/2018

YEAR-OVER-YEAR STATEMENT OF CASH FLOWS

Negative cash from operating activities

Statement of Cash Flows - Year-over-Year - Standardized - Year to Date

(Thousands of U.S. Dollars)

Period Ended	13 weeks 6/1/2019	13 weeks 6/2/2018	13 weeks 6/3/2017	13 weeks 5/28/2016	13 weeks 5/30/2015
			Reclassified 6/2/2018	Reclassified 6/3/2017	
Cash Flows from Operating Activities:					
Net income	(\$99,339)	(\$41,727)	(\$36,037)	(\$4,588)	\$18,836
Depreciation/depletion	83,926	94,529	101,029	138,788	109,649
Deferred taxes	0	(12,355)	(38,160)	(5,749)	9,540
Non-cash Items	(3,242)	(54,499)	62,337	30,849	15,598
Changes in working capital	(46,461)	(76,312)	3,565	700	214,212
Total cash from operating activities	(65,116)	(90,364)	92,734	160,000	367,835
Cash Flows from Investing Activities:					
Capital expenditures	(49,191)	(61,626)	(43,846)	(122,458)	(155,330)
Other investing cash flow items, total	1,181	615,905	(14,350)	3,088	2,838
Total cash from investing activities	(48,010)	554,279	(58,196)	(119,370)	(152,492)
Cash Flows from Financing Activities:					
Financing cash flow items	36,201	(523,961)	27,857	3,089	(65,914)
Issuance/retirement of stock, net	(195)	910	147	2,371	3,378
Issuance/retirement of debt, net	123,220	(241,106)	(93,503)	(25,721)	1,653,423
Total cash from financing activities	159,226	(764,157)	(65,499)	(20,261)	1,590,887
Net change in cash	46,100	(300,242)	(30,961)	20,369	1,806,230
Net cash-beginning balance	144,353	447,334	245,410	124,471	115,899
Net cash-ending balance	\$190,453	\$147,092	\$214,449	\$144,840	\$1,922,129
Supplemental Disclosures:					
Cash interest paid	\$19,462	\$53,553	\$75,535	\$71,434	\$72,194
Cash taxes paid, supplemental	\$830	\$591	\$1,461	\$3,869	\$992
Source:	10-Q 7/11/2019	10-Q 7/6/2018	10-Q 7/6/2018	10-Q 7/6/2017	10-Q 6/22/2015

ABOUT THIS REPORT/CONTACT CREDITRISKMONITOR



CreditRiskMonitor is a financial risk analysis and news service that helps credit, supply chain and financial professionals stay ahead of and manage risk quickly, accurately and cost effectively. More than 35% of the Fortune 1000, plus over a thousand other large corporations worldwide, rely on our financial risk coverage of over 56,000 global public companies.

CreditRiskMonitor's High Risk Reports feature companies that are exhibiting a significantly high level of financial distress, as indicated by our proprietary FRISK® score. The ultimate goal of the High Risk Report series is two-part: provide an early warning for those doing business with an increasingly distressed company and inform of the many signals that should be examined when assessing financial risks.

[Request a Personalized Demo and Risk Assessment](#)

[Read more Bankruptcy Case Studies, High Risk Reports and other resources](#)

Contact us at:

845.230.3000

creditriskmonitor.com/contact-us